New combo aims to fix Chemo-Caused low platelets

NCT ID NCT07334093

Not yet recruiting Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether combining two platelet-boosting drugs (hetrombopag and rhTPO) works better than hetrombopag alone for cancer patients with dangerously low platelets from treatment. About 204 adults with solid tumors will be randomly assigned to one of the two groups. The goal is to see if more patients reach a safe platelet level within two weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hetrombopag and rhTPO (a platelet-boosting drug combination)
What this could lead to: If it works, this could offer a more effective way to raise dangerously low platelet counts in cancer patients, reducing bleeding risks and treatment delays.
What could go wrong: This is an early Phase 2 trial with only 204 participants, so results may not apply to all patients. The combination may not work better than the single drug, and there are risks like excessive platelet increases or side effects from the drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER THERAPY-INDUCED THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired thrombocytopenia chemotherapy-induced toxicity neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER THERAPY-INDUCED THROMBOCYTOPENIA (CTIT)

More trials for these conditions

Other studies related to the condition(s) this trial covers.